A second population, a different gut signal: Parkinson's microbiome study moves to southern China

A new cross-sectional study of 42 Parkinson's patients in Fujian province reports its own pattern of gut bacterial imbalance, the first such look at this population and an independent test of whether microbiome changes reported earlier this year in European and other cohorts hold up elsewhere.

Researchers in Fujian, China, report a distinct pattern of gut bacterial imbalance in people with Parkinson's disease, according to a study published August 3, 2026 in Antonie van Leeuwenhoek. The team analyzed fecal samples from 42 Parkinson's patients and 25 age-matched controls using 16S rRNA gene sequencing, and found significant differences in bacterial composition between the two groups, with particular attention to bacteria that produce short-chain fatty acids, compounds linked to gut and immune health.

The study follows an April 2026 Nature Medicine paper from a UCL-led team, which identified a gut microbiome signature shared between normal aging and Parkinson's in 271 patients, 43 people carrying a Parkinson's-linked gene variant without symptoms, and 150 healthy controls in the UK and Italy, a pattern the same team said it saw again in separate cohorts from the United States, South Korea and Turkey totaling 638 more patients and 319 more controls. None of those cohorts included people from mainland China, so the open question has been whether a similar bacterial pattern turns up in a population with different diet, genetics and geography.

The Fujian team reports that two classes of Parkinson's medication, anticholinergic and dopaminergic drugs, were associated with changes in the abundance of several short-chain-fatty-acid-producing bacteria groups, including Ruminococcaceae, Clostridiales and Blautia, while levels of a bacterium called Alistipes did not vary significantly by medication group in the exploratory analyses the authors ran. The authors describe the bacterial changes as appearing early in the patients they studied and as shaped jointly by disease severity, age and medication, a combination the paper says has not been well separated in prior work on this question.

The authors frame the finding as supporting a role for the gut-brain axis in Parkinson's biology without claiming it as proof of one; the paper stops short of saying the bacterial shifts are a cause, a consequence, or a marker that simply travels alongside the disease and its treatment.

Whether the same signature would appear in a larger Chinese sample, or in people not yet diagnosed, is not something this study was designed to answer.